Echocardiographic and exercise test findings in patients with dyslipidemia and coronary artery disease before and after treatment with simvastatin with or without fenofibrate
International Cardiovascular Research Journal. 2011; 5 (4): 143-147
in English
| IMEMR
| ID: emr-160895
ABSTRACT
Various treatment protocols for dyslipidemia and coronary artery disease have been suggested. In spite of lipid-lowering effects, various effects of statins and fi-brates have been reported in the literature. The aim of this study was to assess the cardiac efficacy of Simvastatin with or without fenofibrate on cardiac function. A cohort study was conducted on 124 patients with dyslipidemia and coronary artery disease. Patients were randomly divided into two groups the first group [n = 64] received Simvastatin [60 - 20 mg/day] and fenofibrate [200 mg/day], and the second group [n = 60] received Simvastatin [20 - 60 mg/day] alone. Treatment lasted l year, and the patients were evaluated after treatment. The mean age was 54.3 + 6.5 years, and 53.2% of patients were male. Compared to baseline, after 12 months of treatment the lipid profiles of both groups decreased significantly [P< 0.05]. The change in left-ventricular ejection fraction in the first group was statistically significant [P = 0.01]. The exercise test time and metabolic equivalent of tasks index significantly increased in the first group [P = 0.014, P = 0.006], but these changes were not significant in the second group [P = 0.289, P = 0.744]. Lipid-regulating therapies including Simvastatin and fenofibrate improved myocardial function and reduced myocardial ischemia, so combined therapy is recommended for treating dyslipidemia in high-risk patients for cardiovascular problems
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Int. Cardiovasc. Res. J.
Year:
2011
Similar
MEDLINE
...
LILACS
LIS